The proprotein convertases in hypercholesterolemia and cardiovascular diseases: Emphasis on proprotein convertase subtilisin/Kexin 9

Pharmacological Reviews

Volumn 69, Issue 1, 2017, Pages 33-52

  Seidah, Nabil G ^a   Abifadel, Marianne ^b,c   Prost, Stefan ^d,e   Boileau, Catherine ^b   Prat, Annik ^a  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^b BICHAT HOSPITAL   (France)

^c SAINT JOSEPH UNIVERSITY   (Lebanon)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FURIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PROPROTEIN CONVERTASE 9; VERY LOW DENSITY LIPOPROTEIN RECEPTOR; BIOLOGICAL MARKER; CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LDLR PROTEIN, HUMAN; LIPOPROTEIN A; PCSK9 PROTEIN, HUMAN; SERINE PROTEINASE INHIBITOR;

ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CELLULAR DISTRIBUTION; DIABETES MELLITUS; ENZYME ACTIVATION; ENZYME DEGRADATION; ENZYME INHIBITION; EXTRACELLULAR MATRIX; GENE LOCUS; HAPLOTYPE; HEART DEVELOPMENT; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PHYLOGENETIC TREE; PHYLOGENY; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY MECHANISM; SEPSIS; TISSUE SPECIFICITY; VIRUS INFECTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; COMPLICATION; ENZYMOLOGY; FEMALE; GENETICS; MALE; METABOLISM; MUTATION; PROTEIN DEGRADATION;

ANIMALS; ANTICHOLESTEREMIC AGENTS; BIOMARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL; FEMALE; HAPLOTYPES; HUMANS; HYPERCHOLESTEROLEMIA; LIPOPROTEIN(A); MALE; MUTATION; PHYLOGENY; PROPROTEIN CONVERTASE 9; PROTEOLYSIS; RECEPTORS, LDL; SERINE PROTEINASE INHIBITORS;

EID: 85006021755     PISSN: 00316997     EISSN: 15210081     Source Type: Journal    
DOI: 10.1124/pr.116.012989     Document Type: Article

References (216)

1. Abifadel M, Elbitar S, El Khoury P, Ghaleb Y, Chémaly M, Moussalli ML, Rabès JP, Varret M, and Boileau C (2014) Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs. Curr Atheroscler Rep 16: 439.
2. Abifadel M, Guerin M, Benjannet S, Rabès JP, Le Goff W, Julia Z, Hamelin J, Carreau V, Varret M, Bruckert E, et al. (2012) Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia. Atherosclerosis 223: 394-400.
3. Abifadel M, Rabès JP, Devillers M, Munnich A, Erlich D, Junien C, Varret M, and Boileau C (2009) Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Hum Mutat 30: 520-529.
4. Abifadel M, Varret M, Rabès JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D, et al. (2003) Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 34: 154-156.
5. Achilleos A, Huffman NT, Marcinkiewicyz E, Seidah NG, Chen Q, Dallas SL, Trainor PA, and Gorski JP (2015) MBTPS1/SKI-1/S1P proprotein convertase is required for ECM signaling and axial elongation during somitogenesis and vertebral development. Hum Mol Genet 24: 2884-2898.
6. Allard D, Amsellem S, Abifadel M, Trillard M, Devillers M, Luc G, Krempf M, Reznik Y, Girardet JP, Fredenrich A, et al. (2005) Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia. Hum Mutat 26: 497-506.
7. Awan Z, Choi HY, Stitziel N, Ruel I, Bamimore MA, Husa R, Gagnon MH, Wang RH, Peloso GM, Hegele RA, et al. (2013) APOE p.Leu167del mutation in familial hypercholesterolemia. Atherosclerosis 231: 218-222.
8. Awan Z, Denis M, Bailey D, Giaid A, Prat A, Goltzman D, Seidah NG, and Genest J (2011) The LDLR deficient mouse as a model for aortic calcification and quantification by micro-computed tomography. Atherosclerosis 219: 455-462.
9. Awan Z, Denis M, Roubtsova A, Essalmani R, Marcinkiewicz J, Awan A, Gram H, Seidah NG, and Genest J (2016) Reducing vascular calcification by anti-IL-1b monoclonal antibody in a mouse model of familial hypercholesterolemia. Angiology 67: 157-167.
10. Ballantyne CM, Neutel J, Cropp A, Duggan W, Wang EQ, Plowchalk D, Sweeney K, Kaila N, Vincent J, and Bays H (2015) Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia. Am J Cardiol 115: 1212-1221.
11. Barale JC, Blisnick T, Fujioka H, Alzari PM, Aikawa M, Braun-Breton C, and Langsley G (1999) Plasmodium falciparum subtilisin-like protease 2, a merozoite candidate for the merozoite surface protein 1-42 maturase. Proc Natl Acad Sci USA 96: 6445-6450.
12. Benjannet S, Hamelin J, Chrétien M, and Seidah NG (2012) Loss- and gain-offunction PCSK9 variants: cleavage specificity, dominant negative effects, and low density lipoprotein receptor (LDLR) degradation. J Biol Chem 287: 33745-33755.
13. Benjannet S, Rhainds D, Essalmani R, Mayne J, Wickham L, Jin W, Asselin MC, Hamelin J, Varret M, Allard D, et al. (2004) NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem 279: 48865-48875.
14. Benjannet S, Rhainds D, Hamelin J, Nassoury N, and Seidah NG (2006) The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications. J Biol Chem 281: 30561-30572.
15. Benjannet S, Rondeau N, Day R, Chrétien M, and Seidah NG (1991) PC1 and PC2 are proprotein convertases capable of cleaving proopiomelanocortin at distinct pairs of basic residues. Proc Natl Acad Sci USA 88: 3564-3568.
16. Berge KE, Ose L, and Leren TP (2006) Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy. Arterioscler Thromb Vasc Biol 26: 1094-1100.
17. Berger JM, Vaillant N, Le May C, Calderon C, Brégeon J, Prieur X, Hadchouel J, Loirand G, and Cariou B (2015) PCSK9-deficiency does not alter blood pressure and sodium balance in mouse models of hypertension. Atherosclerosis 239: 252-259.
18. Blanchet M, Sureau C, Guévin C, Seidah NG, and Labonté P (2015) SKI-1/S1P inhibitor PF-429242 impairs the onset of HCV infection. Antiviral Res 115: 94-104.
19. Bourbon M, Alves AC, Medeiros AM, Silva S, and Soutar AK; Investigators of Portuguese FH Study (2008) Familial hypercholesterolaemia in Portugal. Atherosclerosis 196: 633-642.
20. Boyd JH, Fjell CD, Russell JA, Sirounis D, Cirstea MS, and Walley KR (2016) Increased plasma PCSK9 levels are associated with reduced endotoxin clearance and the development of acute organ failures during sepsis. J Innate Immun 8: 211-220.
21. Bridge SH, Sheridan DA, Felmlee DJ, Crossey MM, Fenwick FI, Lanyon CV, Dubuc G, Seidah NG, Davignon J, Thomas HC, et al. (2015) PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: evidence for genotype-specific regulation of lipoprotein metabolism. J Hepatol 62: 763-770.
22. Brown MS and Goldstein JL (1974) Familial hypercholesterolemia: defective binding of lipoproteins to cultured fibroblasts associated with impaired regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity. Proc Natl Acad Sci USA 71: 788-792.
23. Butkinaree C, Canuel M, Essalmani R, Poirier S, Benjannet S, Asselin M-C, Roubtsova A, Hamelin J, Marcinkiewicz J, Chamberland A, et al. (2015) Amyloid precursor-like protein 2 and sortilin do not regulate the PCSK9 convertasemediated low density lipoprotein receptor degradation but interact with each other. J Biol Chem 290: 18609-18620.
24. Cameron J, Holla OL, Berge KE, Kulseth MA, Ranheim T, Leren TP, and Laerdahl JK (2008) Investigations on the evolutionary conservation of PCSK9 reveal a functionally important protrusion. FEBS J 275: 4121-4133.
25. Cameron J, Holla OL, Ranheim T, Kulseth MA, Berge KE, and Leren TP (2006) Effect of mutations in the PCSK9 gene on the cell surface LDL receptors. Hum Mol Genet 15: 1551-1558.
26. Campan M, Yoshizumi M, Seidah NG, Lee ME, Bianchi C, and Haber E (1996) Increased proteolytic processing of protein tyrosine phosphatase mu in confluent vascular endothelial cells: the role of PC5, a member of the subtilisin family. Biochemistry 35: 3797-3802.
27. Canuel M, Sun X, Asselin M-C, Paramithiotis E, Prat A, and Seidah NG (2013) Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1). PLoS One 8: e64145.
28. Cariou B, Langhi C, Le Bras M, Bortolotti M, Lê KA, Theytaz F, Le May C, Guyomarc’h-Delasalle B, Zaïr Y, Kreis R, et al. (2013) Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets. Nutr Metab 10: 4.
29. Cariou B, Ouguerram K, Zaïr Y, Guerois R, Langhi C, Kourimate S, Benoit I, Le May C, Gayet C, Belabbas K, et al. (2009) PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia. Arterioscler Thromb Vasc Biol 29: 2191-2197.
30. Cenarro A, García-Otín AL, Tejedor MT, Solanas M, Jarauta E, Junquera C, Ros E, Mozas P, Puzo J, Pocoví M, et al. (2011) A presumptive new locus for autosomal dominant hypercholesterolemia mapping to 8q24.22. Clin Genet 79: 475-481.
31. Chen S, Cao P, Dong N, Peng J, Zhang C, Wang H, Zhou T, Yang J, Zhang Y, Martelli EE, et al. (2015) PCSK6-mediated corin activation is essential for normal blood pressure. Nat Med 21: 1048-1053.
32. Chen SN, Ballantyne CM, Gotto AM Jr, Tan Y, Willerson JT, and Marian AJ (2005) A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. J Am Coll Cardiol 45: 1611-1619.
33. Chen XW, Wang H, Bajaj K, Zhang P, Meng ZX, Ma D, Bai Y, Liu HH, Adams E, Baines A, et al. (2013) SEC24A deficiency lowers plasma cholesterol through reduced PCSK9 secretion. eLife 2: e00444.
34. Cheng D, Espenshade PJ, Slaughter CA, Jaen JC, Brown MS, and Goldstein JL (1999) Secreted site-1 protease cleaves peptides corresponding to luminal loop of sterol regulatory element-binding proteins. J Biol Chem 274: 22805-22812.
35. Choquet H, Kasberger J, Hamidovic A, and Jorgenson E (2013) Contribution of common PCSK1 genetic variants to obesity in 8,359 subjects from multi-ethnic American population. PLoS One 8: e57857.
36. Chrétien M (2011) The prohormone theory and the proprotein convertases: it is all about serendipity. Methods Mol Biol 768: 13-19.
37. Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, and Hobbs HH (2005) Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 37: 161-165.
38. Cohen JC, Boerwinkle E, Mosley TH Jr, and Hobbs HH (2006) Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 354: 1264-1272.
39. Creemers JW, Choquet H, Stijnen P, Vatin V, Pigeyre M, Beckers S, Meulemans S, Than ME, Yengo L, Tauber M, et al. (2012) Heterozygous mutations causing partial prohormone convertase 1 deficiency contribute to human obesity. Diabetes 61: 383-390.
40. Creemers JW and Khatib AM (2008) Knock-out mouse models of proprotein convertases: unique functions or redundancy? Front Biosci 13: 4960-4971.
41. Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, Malcangi V, Petrini F, Volta G, Bobbio Pallavicini FM, et al. (2009) Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 301: 2445-2452.
42. Cui CJ, Li S, and Li JJ (2015) PCSK9 and its modulation. Clin Chim Acta 440: 79-86.
43. Cunningham D, Danley DE, Geoghegan KF, Griffor MC, Hawkins JL, Subashi TA, Varghese AH, Ammirati MJ, Culp JS, Hoth LR, et al. (2007) Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat Struct Mol Biol 14: 413-419.
44. Dannemann M, Andrés AM, and Kelso J (2016) Introgression of neandertal- and denisovan-like haplotypes contributes to adaptive variation in human Toll-like receptors. Am J Hum Genet 98: 22-33.
45. Demers A, Samami S, Lauzier B, Des Rosiers C, Ngo Sock ET, Ong H, and Mayer G (2015) PCSK9 induces CD36 degradation and affects long-chain fatty acid uptake and triglyceride metabolism in adipocytes and in mouse liver. Arterioscler Thromb Vasc Biol 35: 2517-2525.
46. DeVay RM, Shelton DL, and Liang H (2013) Characterization of proprotein convertase subtilisin/kexin type 9 (PCSK9) trafficking reveals a novel lysosomal targeting mechanism via amyloid precursor-like protein 2 (APLP2). J Biol Chem 288: 10805-10818.
47. Dewpura T, Raymond A, Hamelin J, Seidah NG, Mbikay M, Chrétien M, and Mayne J (2008) PCSK9 is phosphorylated by a Golgi casein kinase-like kinase ex vivo and circulates as a phosphoprotein in humans. FEBS J 275: 3480-3493.
48. Ding K, McDonough SJ, and Kullo IJ (2007) Evidence for positive selection in the C-terminal domain of the cholesterol metabolism gene PCSK9 based on phylogenetic analysis in 14 primate species. PLoS One 2: e1098.
49. Dong B, Li H, Singh AB, Cao A, and Liu J (2015) Inhibition of PCSK9 transcription by berberine involves down-regulation of hepatic HNF1a protein expression through the ubiquitin-proteasome degradation pathway. J Biol Chem 290: 4047-4058.
50. Dong B, Wu M, Li H, Kraemer FB, Adeli K, Seidah NG, Park SW, and Liu J (2010) Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters. J Lipid Res 51: 1486-1495.
51. dos Santos C and Marshall JC (2014) Bridging lipid metabolism and innate host defense. Sci Transl Med 6: 258fs41.
52. Dubé E, Ethier-Chiasson M, and Lafond J (2013) Modulation of cholesterol transport by insulin-treated gestational diabetes mellitus in human full-term placenta. Biol Reprod 88: 16.
53. Dubuc G, Chamberland A, Wassef H, Davignon J, Seidah NG, Bernier L, and Prat A (2004) Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 24: 1454-1459.
54. Dubuc G, Tremblay M, Paré G, Jacques H, Hamelin J, Benjannet S, Boulet L, Genest J, Bernier L, Seidah NG, et al. (2010) A new method for measurement of total plasma PCSK9: clinical applications. J Lipid Res 51: 140-149.
55. Dwivedi DJ, Grin PM, Khan M, Prat A, Zhou J, Fox-Robichaud AE, Seidah NG, and Liaw PC (2016) Differential expression of PCSK9 modulates infection, inflammation and coagulation in a murine model of sepsis. Shock, in press.
56. Elbitar S, Khoury PE, Ghaleb Y, Rabès JP, Varret M, Seidah NG, Boileau C, and Abifadel M (2016) Proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011-2015). Expert Opin Ther Pat1-16.
57. Espenshade PJ, Cheng D, Goldstein JL, and Brown MS (1999) Autocatalytic processing of site-1 protease removes propeptide and permits cleavage of sterol regulatory element-binding proteins. J Biol Chem 274: 22795-22804.
58. Essalmani R, Susan-Resiga D, Chamberland A, Abifadel M, Creemers JW, Boileau C, Seidah NG, and Prat A (2011) In vivo evidence that furin from hepatocytes inactivates PCSK9. J Biol Chem 286: 4257-4263.
59. Essalmani R, Zaid A, Marcinkiewicz J, Chamberland A, Pasquato A, Seidah NG, and Prat A (2008) In vivo functions of the proprotein convertase PC5/6 during mouse development: Gdf11 is a likely substrate. Proc Natl Acad Sci USA 105: 5750-5755.
60. Fasano T, Cefalù AB, Di Leo E, Noto D, Pollaccia D, Bocchi L, Valenti V, Bonardi R, Guardamagna O, Averna M, et al. (2007) A novel loss of function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterol. Arterioscler Thromb Vasc Biol 27: 677-681.
61. Fasano T, Sun XM, Patel DD, and Soutar AK (2009) Degradation of LDLR protein mediated by ‘gain of function’ PCSK9 mutants in normal and ARH cells. Atherosclerosis 203: 166-171.
62. Feingold KR, Moser AH, Shigenaga JK, Patzek SM, and Grunfeld C (2008) Inflammation stimulates the expression of PCSK9. Biochem Biophys Res Commun 374: 341-344.
63. Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S, Liebow A, Bettencourt BR, Sutherland JE, Hutabarat RM, Clausen VA, Karsten V, Cehelsky J, et al. (2014) Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet 383: 60-68.
64. Flynn TG, de Bold ML, and de Bold AJ (1983) The amino acid sequence of an atrial peptide with potent diuretic and natriuretic properties. Biochem Biophys Res Commun 117: 859-865.
65. Fouchier SW, Dallinga-Thie GM, Meijers JC, Zelcer N, Kastelein JJ, Defesche JC, and Hovingh GK (2014) Mutations in STAP1 are associated with autosomal dominant hypercholesterolemia. Circ Res 115: 552-555.
66. Gaieski DF, Edwards JM, Kallan MJ, and Carr BG (2013) Benchmarking the incidence and mortality of severe sepsis in the United States. Crit Care Med 41: 1167-1174.
67. Garcia CK, Wilund K, Arca M, Zuliani G, Fellin R, Maioli M, Calandra S, Bertolini S, Cossu F, Grishin N, et al. (2001) Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. Science 292: 1394-1398.
68. Gauthier MS, Pérusse JR, Awan Z, Bouchard A, Tessier S, Champagne J, Krastins B, Byram G, Chabot K, Garneau P, et al. (2015) A semi-automated mass spectrometric immunoassay coupled to selected reaction monitoring (MSIA-SRM) reveals novel relationships between circulating PCSK9 and metabolic phenotypes in patient cohorts. Methods 81: 66-73.
69. Gorski JP, Huffman NT, Vallejo J, Brotto L, Chittur SV, Breggia A, Stern A, Huang J, Mo C, Seidah NG, et al. (2016) Deletion of Mbtps1 (Pcsk8, S1p, Ski-1) gene in osteocytes stimulates soleus muscle regeneration and increased size and contractile force with age. J Biol Chem 291: 4308-4322.
70. Guillemot J, Essalmani R, Hamelin J, and Seidah NG (2014) Is there a link between proprotein convertase PC7 activity and human lipid homeostasis? FEBS Open Bio 4: 741-745.
71. Gustafsen C, Kjolby M, Nyegaard M, Mattheisen M, Lundhede J, Buttenschøn H, Mors O, Bentzon JF, Madsen P, Nykjaer A, et al. (2014) The hypercholesterolemiarisk gene SORT1 facilitates PCSK9 secretion. Cell Metab 19: 310-318.
72. Han B, Eacho PI, Knierman MD, Troutt JS, Konrad RJ, Yu X, and Schroeder KM (2014) Isolation and characterization of the circulating truncated form of PCSK9. J Lipid Res 55: 1505-1514.
73. Hawkins JL, Robbins MD, Warren LC, Xia D, Petras SF, Valentine JJ, Varghese AH, Wang IK, Subashi TA, Shelly LD, et al. (2008) Pharmacologic inhibition of site 1 protease activity inhibits sterol regulatory element-binding protein processing and reduces lipogenic enzyme gene expression and lipid synthesis in cultured cells and experimental animals. J Pharmacol Exp Ther 326: 801-808.
74. He XM, Chen L, Wang TS, Zhang YB, Luo JB, and Feng XX (2016) E670G polymorphism of PCSK9 gene of patients with coronary heart disease among Han population in Hainan and three provinces in the northeast of China. Asian Pac J Trop Med 9: 172-176.
75. Holla OL, Strøm TB, Cameron J, Berge KE, and Leren TP (2010) A chimeric LDL receptor containing the cytoplasmic domain of the transferrin receptor is degraded by PCSK9. Mol Genet Metab 99: 149-156.
76. Homer VM, Marais AD, Charlton F, Laurie AD, Hurndell N, Scott R, Mangili F, Sullivan DR, Barter PJ, Rye KA, et al. (2008) Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa. Atherosclerosis 196: 659-666.
77. Hoogeveen RC, Gaubatz JW, Sun W, Dodge RC, Crosby JR, Jiang J, Couper D, Virani SS, Kathiresan S, Boerwinkle E, et al. (2014) Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: the Atherosclerosis Risk In Communities (ARIC) study. Arterioscler Thromb Vasc Biol 34: 1069-1077.
78. Hooper AJ, Marais AD, Tanyanyiwa DM, and Burnett JR (2007) The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis 193: 445-448.
79. Hopkins PN, Defesche J, Fouchier SW, Bruckert E, Luc G, Cariou B, Sjouke B, Leren TP, Harada-Shiba M, Mabuchi H, et al. (2015) Characterization of autosomal dominant hypercholesterolemia caused by PCSK9 gain of function mutations and its specific treatment with alirocumab, a PCSK9 monoclonal antibody. Circ Cardiovasc Genet 8: 823-831.
80. Huang T, Huang J, Qi Q, Li Y, Bray GA, Rood J, Sacks FM, and Qi L (2015) PCSK7 genotype modifies effect of a weight-loss diet on 2-year changes of insulin resistance: the POUNDS LOST trial. Diabetes Care 38: 439-444.
81. Huerta-Sánchez E, Jin X, Asan, Bianba Z, Peter BM, Vinckenbosch N, Liang Y, Yi X, He M, Somel M, et al. (2014) Altitude adaptation in Tibetans caused by introgression of Denisovan-like DNA. Nature 512: 194-197.
82. Hunt SC, Hopkins PN, Bulka K, McDermott MT, Thorne TL, Wardell BB, Bowen BR, Ballinger DG, Skolnick MH, and Samuels ME (2000) Genetic localization to chromosome 1p32 of the third locus for familial hypercholesterolemia in a Utah kindred. Arterioscler Thromb Vasc Biol 20: 1089-1093.
83. Iatan I, Dastani Z, Do R, Weissglas-Volkov D, Ruel I, Lee JC, Huertas-Vazquez A, Taskinen MR, Prat A, Seidah NG, et al. (2009) Genetic variation at the proprotein convertase subtilisin/kexin type 5 gene modulates high-density lipoprotein cholesterol levels. Circ Cardiovasc Genet 2: 467-475.
84. Innerarity TL, Weisgraber KH, Arnold KS, Mahley RW, Krauss RM, Vega GL, and Grundy SM (1987) Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding. Proc Natl Acad Sci USA 84: 6919-6923.
85. Ito MK and Santos RD (2016) PCSK9 inhibition with monoclonal antibodies: modern management of hypercholesterolemia. J Clin Pharmacol DOI: 10.1002/jcph.766 [published ahead of print].
86. Jackson RS, Creemers JW, Ohagi S, Raffin-Sanson ML, Sanders L, Montague CT, Hutton JC, and O’Rahilly S (1997) Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene. Nat Genet 16: 303-306.
87. Jang HB, Hwang JY, Park JE, Oh JH, Ahn Y, Kang JH, Park KH, Han BG, Kim BJ, Park SI, et al. (2014) Intake levels of dietary polyunsaturated fatty acids modify the association between the genetic variation in PCSK5 and HDL cholesterol. J Med Genet 51: 782-788.
88. Jin W, Fuki IV, Seidah NG, Benjannet S, Glick JM, and Rader DJ (2005) Proprotein convertases [corrected] are responsible for proteolysis and inactivation of endothelial lipase. J Biol Chem 280: 36551-36559.
89. Julius D, Brake A, Blair L, Kunisawa R, and Thorner J (1984) Isolation of the putative structural gene for the lysine-arginine-cleaving endopeptidase required for processing of yeast prepro-alpha-factor. Cell 37: 1075-1089.
90. Kamani CH, Gencer B, Montecucco F, Courvoisier D, Vuilleumier N, Meyer P, and Mach F (2015) Stairs instead of elevators at the workplace decreases PCSK9 levels in a healthy population. Eur J Clin Invest 45: 1017-1024.
91. Kathiresan S, Melander O, Guiducci C, Surti A, Burtt NP, Rieder MJ, Cooper GM, Roos C, Voight BF, Havulinna AS, et al. (2008) Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet 40: 189-197.
92. Khachadurian AK (1964) The inheritance of essential familial hypercholesterolemia. Am J Med 37: 402-407.
93. Khovidhunkit W, Kim MS, Memon RA, Shigenaga JK, Moser AH, Feingold KR, and Grunfeld C (2004) Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 45: 1169-1196.
94. Kim W, Essalmani R, Szumska D, Creemers JW, Roebroek AJ, D’Orleans-Juste P, Bhattacharya S, Seidah NG, and Prat A (2012) Loss of endothelial furin leads to cardiac malformation and early postnatal death. Mol Cell Biol 32: 3382-3391.
95. Kim W, Zekas E, Lodge R, Susan-Resiga D, Marcinkiewicz E, Essalmani R, Mihara K, Ramachandran R, Asahchop E, Gelman B, et al. (2015) Neuroinflammationinduced interactions between protease-activated receptor 1 and proprotein convertases in HIV-associated neurocognitive disorder. Mol Cell Biol 35: 3684-3700.
96. KonarzewskiM, SzolkiewiczM, Sucajtys-Szulc E, Blaszak J, Lizakowski S, Swierczynski J, and Rutkowski B (2014) Elevated circulating PCSK-9 concentration in renal failure patients is corrected by renal replacement therapy. Am J Nephrol 40: 157-163.
97. Koop EA, Lopes SM, Feiken E, Bluyssen HA, van der Valk M, Voest EE, Mummery CL, Moolenaar WH, and Gebbink MF (2003) Receptor protein tyrosine phosphatase mu expression as a marker for endothelial cell heterogeneity; analysis of RPTPmu gene expression using LacZ knock-in mice. Int J Dev Biol 47: 345-354.
98. Kosenko T, Golder M, Leblond G, Weng W, and Lagace TA (2013) Low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation. J Biol Chem 288: 8279-8288.
99. Kotowski IK, Pertsemlidis A, Luke A, Cooper RS, Vega GL, Cohen JC, and Hobbs HH (2006) A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am J Hum Genet 78: 410-422.
100. Kwon HJ, Lagace TA, McNutt MC, Horton JD, and Deisenhofer J (2008) Molecular basis for LDL receptor recognition by PCSK9. Proc Natl Acad Sci USA 105: 1820-1825.
101. Labonté P, Begley S, Guévin C, Asselin MC, Nassoury N, Mayer G, Prat A, and Seidah NG (2009) PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression. Hepatology 50: 17-24.
102. Lagace TA (2014) PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells. Curr Opin Lipidol 25: 387-393.
103. Lagace TA, Curtis DE, Garuti R, McNutt MC, Park SW, Prather HB, Anderson NN, Ho YK, Hammer RE, and Horton JD (2006) Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest 116: 2995-3005.
104. Lambert G, Jarnoux AL, Pineau T, Pape O, Chetiveaux M, Laboisse C, Krempf M, and Costet P (2006) Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor. Endocrinology 147: 4985-4995.
105. Langhi C, Le May C, Gmyr V, Vandewalle B, Kerr-Conte J, Krempf M, Pattou F, Costet P, and Cariou B (2009) PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion. Biochem Biophys Res Commun 390: 1288-1293.
106. Lanza-Jacoby S, Miller S, Jacob S, Heumann D, Minchenko AG, and Flynn JT (2003) Hyperlipoproteinemic low-density lipoprotein receptor-deficient mice are more susceptible to sepsis than corresponding wild-type mice. J Endotoxin Res 9: 341-347.
107. Lappegård KT, Enebakk T, Thunhaug H, and Hovland A (2016) Transition from LDL apheresis to evolocumab in heterozygous FH is equally effective in lowering LDL, without lowering HDL cholesterol. Atherosclerosis 251: 119-123.
108. Le May C, Berger JM, Lespine A, Pillot B, Prieur X, Letessier E, Hussain MM, Collet X, Cariou B, and Costet P (2013) Transintestinal cholesterol excretion is an active metabolic process modulated by PCSK9 and statin involving ABCB1. Arterioscler Thromb Vasc Biol 33: 1484-1493.
109. Le QT, Blanchet M, Seidah NG, and Labonte P (2015) Plasma membrane tetraspanin CD81 complexes with proprotein convertase subtilisin/kexin type 9 (PCSK9) and low density lipoprotein receptor (LDLR), and its levels are reduced by PCSK9. J Biol Chem 290: 23385-23400.
110. Leander K, Malarstig A, van’t Hooft FM, Hyde C, Hellenius ML, Troutt JS, Konrad RJ, Ohrvik J, and Hamsten A and de Faire U ( (2016) Circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) predicts future risk of cardiovascular events independently of established risk factors. Circulation 133: 1230-1239.
111. Lei X, Shi F, Basu D, Huq A, Routhier S, Day R, and Jin W (2011) Proteolytic processing of angiopoietin-like protein 4 by proprotein convertases modulates its inhibitory effects on lipoprotein lipase activity. J Biol Chem 286: 15747-15756.
112. Leren TP (2004) Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia. Clin Genet 65: 419-422.
113. Leren TP (2014) Sorting an LDL receptor with bound PCSK9 to intracellular degradation. Atherosclerosis 237: 76-81.
114. Li H, Dong B, Park SW, Lee HS, Chen W, and Liu J (2009) Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine. J Biol Chem 284: 28885-28895.
115. Li JP, Wang XB, Chen CZ, Xu X, Hong XM, Xu XP, Gao W, and Huo Y (2004) The association between paired basic amino acid cleaving enzyme 4 gene haplotype and diastolic blood pressure. Chin Med J 117: 382-388.
116. Liao W, Rudling M, and Angelin B (1996) Endotoxin suppresses rat hepatic lowdensity lipoprotein receptor expression. Biochem J 313: 873-878.
117. Lo Surdo P, Bottomley MJ, Calzetta A, Settembre EC, Cirillo A, Pandit S, Ni YG, Hubbard B, Sitlani A, and Carfí A (2011) Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH. EMBO Rep 12: 1300-1305.
118. Mabuchi H, Nohara A, Noguchi T, Kobayashi J, Kawashiri MA, Inoue T, Mori M, Tada H, Nakanishi C, Yagi K, et al.; Hokuriku FH Study Group (2014) Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin/kexin type 9 (PCSK9) gain-of-function mutation. Atherosclerosis 236: 54-61.
119. Marchesi C, Essalmani R, Lemarié CA, Leibovitz E, Ebrahimian T, Paradis P, Seidah NG, Schiffrin EL, and Prat A (2011) Inactivation of endothelial proprotein convertase 5/6 decreases collagen deposition in the cardiovascular system: role of fibroblast autophagy. J Mol Med 89: 1103-1111.
120. Marduel M, Ouguerram K, Serre V, Bonnefont-Rousselot D, Marques-Pinheiro A, Erik Berge K, Devillers M, Luc G, Lecerf JM, Tosolini L, et al.; French Research Network on ADH (2013) Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation. Hum Mutat 34: 83-87.
121. Marques-Pinheiro A, Marduel M, Rabès JP, Devillers M, Villéger L, Allard D, Weissenbach J, Guerin M, Zair Y, Erlich D, et al.; French Research Network on ADH (2010) A fourth locus for autosomal dominant hypercholesterolemia maps at 16q22.1. Eur J Hum Genet 18: 1236-1242.
122. Maxwell KN and Breslow JL (2004) Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc Natl Acad Sci USA 101: 7100-7105.
123. Maxwell KN, Soccio RE, Duncan EM, Sehayek E, and Breslow JL (2003) Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice. J Lipid Res 44: 2109-2119.
124. Mayne J, Dewpura T, Raymond A, Bernier L, Cousins M, Ooi TC, Davignon J, Seidah NG, Mbikay M, and Chrétien M (2011) Novel loss-of-function PCSK9 variant is associated with low plasma LDL cholesterol in a French-Canadian family and with impaired processing and secretion in cell culture. Clin Chem 57: 1415-1423.
125. McNutt MC, Kwon HJ, Chen C, Chen JR, Horton JD, and Lagace TA (2009) Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells. J Biol Chem 284: 10561-10570.
126. McPherron AC, Lawler AM, and Lee SJ (1999) Regulation of anterior/posterior patterning of the axial skeleton by growth/differentiation factor 11. Nat Genet 22: 260-264.
127. Mitchell KJ, Pinson KI, Kelly OG, Brennan J, Zupicich J, Scherz P, Leighton PA, Goodrich LV, Lu X, Avery BJ, et al. (2001) Functional analysis of secreted and transmembrane proteins critical to mouse development. Nat Genet 28: 241-249.
128. Miyake Y, Kimura R, Kokubo Y, Okayama A, Tomoike H, Yamamura T, and Miyata T (2008) Genetic variants in PCSK9 in the Japanese population: rare genetic variants in PCSK9 might collectively contribute to plasma LDL cholesterol levels in the general population. Atherosclerosis 196: 29-36.
129. Mizuno K, Nakamura T, Ohshima T, Tanaka S, and Matsuo H (1988) Yeast KEX2 genes encode an endopeptidase homologous to subtilisin-like serine proteases. Biochem Biophys Res Commun 156: 246-254.
130. Muller PY and Miserez AR (2002) Identification of mutations in the gene encoding sterol regulatory element binding protein (SREBP)-2 in hypercholesterolaemic subjects. J Med Genet 39: 271-275.
131. Naoumova RP, Tosi I, Patel D, Neuwirth C, Horswell SD, Marais AD, van Heyningen C, and Soutar AK (2005) Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response. Arterioscler Thromb Vasc Biol 25: 2654-2660.
132. Nassoury N, Blasiole DA, Tebon Oler A, Benjannet S, Hamelin J, Poupon V, McPherson PS, Attie AD, Prat A, and Seidah NG (2007) The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR. Traffic 8: 718-732.
133. Naureckiene S, Ma L, Sreekumar K, Purandare U, Lo CF, Huang Y, Chiang LW, Grenier JM, Ozenberger BA, Jacobsen JS, et al. (2003) Functional characterization of Narc 1, a novel proteinase related to proteinase K. Arch Biochem Biophys 420: 55-67.
134. Ni YG, Condra JH, Orsatti L, Shen X, Di Marco S, Pandit S, Bottomley MJ, Ruggeri L, Cummings RT, Cubbon RM, et al. (2010) A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake. J Biol Chem 285: 12882-12891.
135. Ouguerram K, Chetiveaux M, Zair Y, Costet P, Abifadel M, Varret M, Boileau C, Magot T, and Krempf M (2004) Apolipoprotein B100 metabolism in autosomaldominant hypercholesterolemia related to mutations in PCSK9. Arterioscler Thromb Vasc Biol 24: 1448-1453.
136. Park SW, Moon YA, and Horton JD (2004) Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J Biol Chem 279: 50630-50638.
137. Parker RA, Garcia R, Ryan CS, Liu X, Shipkova P, Livanov V, Patel P, and Ho SP (2013) Bile acid and sterol metabolism with combined HMG-CoA reductase and PCSK9 suppression. J Lipid Res 54: 2400-2409.
138. Pasquato A and Kunz S (2016) Novel drug discovery approaches for treating arenavirus infections. Expert Opin Drug Discov 11: 383-393.
139. Pasquato A, Rochat C, Burri DJ, Pasqual G, de la Torre JC, and Kunz S (2012) Evaluation of the anti-arenaviral activity of the subtilisin kexin isozyme-1/site-1 protease inhibitor PF-429242. Virology 423: 14-22.
140. Patel AP, Peloso GM, Pirruccelloa JP, Johansen CT, Dubé JB, Larache DB, Band MR, Dallinge-Thief GM, Gupta N, Boehnke M, Abecasis GR, Kastelein JJP, Hovingh GK, Hegele RA, Rader DJ, and Kathiresan S (2016) Targeted exonic sequencing of GWAS loci in the high extremes of the plasma lipids distribution. Atherosclerosis 250: 63-68.
141. Peloso GM, Auer PL, Bis JC, Voorman A, Morrison AC, Stitziel NO, Brody JA, Khetarpal SA, Crosby JR, Fornage M, et al.; NHLBI GO Exome Sequencing Project (2014) Association of low-frequency and rare coding-sequence variants with blood lipids and coronary heart disease in 56,000 whites and blacks. Am J Hum Genet 94: 223-232.
142. Pisciotta L, Priore Oliva C, Cefalù AB, Noto D, Bellocchio A, Fresa R, Cantafora A, Patel D, Averna M, Tarugi P, et al. (2006) Additive effect of mutations in LDLR and PCSK9 genes on the phenotype of familial hypercholesterolemia. Atherosclerosis 186: 433-440.
143. Poirier S, Hamouda HA, Villeneuve L, Demers A, and Mayer G (2016) Trafficking dynamics of PCSK9-induced LDLR degradation: focus on human PCSK9 mutations and C-terminal domain. PLoS One 11: e0157230.
144. Poirier S, Mamarbachi M, Chen WT, Lee AS, and Mayer G (2015) GRP94 regulates circulating cholesterol levels through blockade of PCSK9-induced LDLR degradation. Cell Reports 13: 2064-2071.
145. Poirier S, Mayer G, Benjannet S, Bergeron E, Marcinkiewicz J, Nassoury N, Mayer H, Nimpf J, Prat A, and Seidah NG (2008) The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J Biol Chem 283: 2363-2372.
146. Prüfer K, Racimo F, Patterson N, Jay F, Sankararaman S, Sawyer S, Heinze A, Renaud G, Sudmant PH, de Filippo C, et al. (2014) The complete genome sequence of a Neanderthal from the Altai Mountains. Nature 505: 43-49.
147. Pullinger CR, Eng C, Salen G, Shefer S, Batta AK, Erickson SK, Verhagen A, Rivera CR, Mulvihill SJ, Malloy MJ, et al. (2002) Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. J Clin Invest 110: 109-117.
148. Raal FJ, Giugliano RP, Sabatine MS, Koren MJ, Blom D, Seidah NG, Honarpour N, Lira A, Xue A, Chiruvolu P, et al. (2016) PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor’s role. J Lipid Res 57: 1086-1096.
149. Raal FJ, Honarpour N, Blom DJ, Hovingh GK, Xu F, Scott R, Wasserman SM, and Stein EA; TESLA Investigators (2015) Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet 385: 341-350.
150. Racimo F, Marnetto D, and Huerta-Sanchez E (2016) Signatures of archaic adaptive introgression in present-day human populations. Mol Biol Evol, in press.
151. Ramos-Molina B, Martin MG, and Lindberg I (2016) PCSK1 variants and human obesity. Prog Mol Biol Transl Sci 140: 47-74.
152. Rashid S, Curtis DE, Garuti R, Anderson NN, Bashmakov Y, Ho YK, Hammer RE, Moon YA, and Horton JD (2005) Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci USA 102: 5374-5379.
153. Rawson RB, Zelenski NG, Nijhawan D, Ye J, Sakai J, Hasan MT, Chang TY, Brown MS, and Goldstein JL (1997) Complementation cloning of S2P, a gene encoding a putative metalloprotease required for intramembrane cleavage of SREBPs. Mol Cell 1: 47-57.
154. Rey J, Poitiers F, Paehler T, Brunet A, DiCioccio AT, Cannon CP, Surks HK, Pinquier JL, Hanotin C, and Sasiela WJ (2016) Relationship between low-density lipoprotein cholesterol, free proprotein convertase subtilisin/kexin type 9, and alirocumab levels after different lipid-lowering strategies. J Am Heart Assoc 5: e003323.
155. Richard C, Couture P, Desroches S, Benjannet S, Seidah NG, Lichtenstein AH, and Lamarche B (2012) Effect of the Mediterranean diet with and without weight loss on surrogate markers of cholesterol homeostasis in men with the metabolic syndrome. Br J Nutr 107: 705-711.
156. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M, et al.; ODYSSEY LONG TERM Investigators (2015) Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 372: 1489-1499.
157. Roebroek AJ, Umans L, Pauli IG, Robertson EJ, van Leuven F, Van de Ven WJ, and Constam DB (1998) Failure of ventral closure and axial rotation in embryos lacking the proprotein convertase Furin. Development 125: 4863-4876.
158. Romagnuolo R, Scipione CA, Boffa MB, Marcovina SM, Seidah NG, and KoschinskyML (2015) Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor. J Biol Chem 290: 11649-11662.
159. Roubtsova A, Chamberland A, Marcinkiewicz J, Essalmani R, Fazel A, Bergeron JJ, Seidah NG, and Prat A (2015) PCSK9 deficiency unmasks a sex- and tissue-specific subcellular distribution of the LDL and VLDL receptors in mice. J Lipid Res 56: 2133-2142.
160. Roubtsova A, Munkonda MN, Awan Z, Marcinkiewicz J, Chamberland A, Lazure C, Cianflone K, Seidah NG, and Prat A (2011) Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue. Arterioscler Thromb Vasc Biol 31: 785-791.
161. Rousselet E, Marcinkiewicz J, Kriz J, Zhou A, Hatten ME, Prat A, and Seidah NG (2011) PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke. J Lipid Res 52: 1383-1391.
162. Saavedra YG, Day R, and Seidah NG (2012) The M2 module of the Cys-His-rich domain (CHRD) of PCSK9 protein is needed for the extracellular low-density lipoprotein receptor (LDLR) degradation pathway. J Biol Chem 287: 43492-43501.
163. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, et al.; Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators (2015) Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.NEngl JMed 372: 1500-1509.
164. Savva A and Roger T (2013) Targeting Toll-like receptors: promising therapeutic strategies for the management of sepsis-associated pathology and infectious diseases. Front Immunol 4: 387.
165. Scartezini M, Hubbart C, Whittall RA, Cooper JA, Neil AH, and Humphries SE (2007) The PCSK9 gene R46L variant is associated with lower plasma lipid levels and cardiovascular risk in healthy U.K. men. Clin Sci 113: 435-441.
166. Schafer MJ, Atkinson EJ, Vanderboom PM, Kotajarvi B, White TA, Moore MM, Bruce CJ, Greason KL, Suri RM, Khosla S, et al. (2016) Quantification of GDF11 and myostatin in human aging and cardiovascular disease. Cell Metab 23: 1207-1215.
167. Schiele F, Park J, Redemann N, Luippold G, and Nar H (2014) An antibody against the C-terminal domain of PCSK9 lowers LDL cholesterol levels in vivo. J Mol Biol 426: 843-852.
168. Schroeder KM, Beyer TP, Hansen RJ, Han B, Pickard RT, Wroblewski VJ, Kowala MC, and Eacho PI (2015) Proteolytic cleavage of antigen extends the durability of an anti-PCSK9 monoclonal antibody. J Lipid Res 56: 2124-2132.
169. Seidah NG (2013) Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors in the treatment of hypercholesterolemia and other pathologies. Curr Pharm Des 19: 3161-3172.
170. Seidah NG (2015) The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol. Journal of Global Cardiology Science and Practice 59: 1-19.
171. Seidah NG (2016) New developments in proprotein convertase subtilisin-kexin 9‘s biology and clinical implications. Curr Opin Lipidol 27: 274-281.
172. Seidah NG, Awan Z, Chrétien M, and Mbikay M (2014) PCSK9: a key modulator of cardiovascular health. Circ Res 114: 1022-1036.
173. Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin SB, Stifani S, Basak A, Prat A, and Chrétien M (2003) The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci USA 100: 928-933.
174. Seidah NG and Chrétien M (1999) Proprotein and prohormone convertases: a family of subtilases generating diverse bioactive polypeptides. Brain Res 848: 45-62.
175. Seidah NG and Guillemot J (2016) Posttranslational processing of secretory proteins, inMolecular Neuroendocrinology: From Genome to Physiology (Murphy D and Gainer H eds) pp 171-194, Wiley-Blackwell, New York.
176. Seidah NG, Hamelin J, Mamarbachi M, Dong W, Tardos H, Mbikay M, Chrétien M, and Day R (1996) cDNA structure, tissue distribution, and chromosomal localization of rat PC7, a novel mammalian proprotein convertase closest to yeast kexinlike proteinases. Proc Natl Acad Sci USA 93: 3388-3393.
177. Seidah NG, Lazure C, Chrétien M, Thibault G, Garcia R, Cantin M, Genest J, Nutt RF, Brady SF, Lyle TA, et al. (1984) Amino acid sequence of homologous rat atrial peptides: natriuretic activity of native and synthetic forms. Proc Natl Acad Sci USA 81: 2640-2644.
178. Seidah NG, Mayer G, Zaid A, Rousselet E, Nassoury N, Poirier S, Essalmani R, and Prat A (2008) The activation and physiological functions of the proprotein convertases. Int J Biochem Cell Biol 40: 1111-1125.
179. Seidah NG, Mowla SJ, Hamelin J, Mamarbachi AM, Benjannet S, Touré BB, Basak A, Munzer JS, Marcinkiewicz J, Zhong M, et al. (1999) Mammalian subtilisin/kexin isozyme SKI-1: a widely expressed proprotein convertase with a unique cleavage specificity and cellular localization. Proc Natl Acad Sci USA 96: 1321-1326.
180. Seidah NG and Prat A (2007) The proprotein convertases are potential targets in the treatment of dyslipidemia. J Mol Med 85: 685-696.
181. Seidah NG and Prat A (2012) The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov 11: 367-383.
182. Seidah NG, Sadr MS, Chrétien M, and Mbikay M (2013) The multifaceted proprotein convertases: their unique, redundant, complementary, and opposite functions. J Biol Chem 288: 21473-21481.
183. Smeekens SP, Montag AG, Thomas G, Albiges-Rizo C, Carroll R, Benig M, Phillips LA, Martin S, Ohagi S, Gardner P, et al. (1992) Proinsulin processing by the subtilisin-related proprotein convertases furin, PC2, and PC3. Proc Natl Acad Sci USA 89: 8822-8826.
184. Stein EA (2013) Low-density lipoprotein cholesterol reduction by inhibition of PCSK9. Curr Opin Lipidol 24: 510-517.
185. Stein EA (2016) What role will proprotein convertase subtilisin/kexin type 9 inhibitors play in hyperlipidemia management? Curr Opin Endocrinol Diabetes Obes 23: 97-105.
186. Stein EA and Raal F (2014) Reduction of low-density lipoprotein cholesterol by monoclonal antibody inhibition of PCSK9. Annu Rev Med 65: 417-431.
187. Steiner DF (2011) On the discovery of precursor processing.MethodsMol Biol 768: 3-11.
188. Stijnen P, Ramos-Molina B, O’Rahilly S, and Creemers JW (2016) PCSK1 mutations and human endocrinopathies: from obesity to gastrointestinal disorders. Endocr Rev 37: 347-371.
189. Stitziel NO, Peloso GM, Abifadel M, Cefalu AB, Fouchier S, Motazacker MM, Tada H, Larach DB, Awan Z, Haller JF, et al. (2015) Exome sequencing in suspected monogenic dyslipidemias. Circ Cardiovasc Genet 8: 343-350.
190. Sucajtys-Szulc E, Szolkiewicz M, Swierczynski J, and Rutkowski B (2016) Upregulation of Hnf1a gene expression in the liver of rats with experimentally induced chronic renal failure: a possible link between circulating PCSK9 and triacylglycerol concentrations. Atherosclerosis 248: 17-26.
191. Sun XM, Eden ER, Tosi I, Neuwirth CK, Wile D, Naoumova RP, and Soutar AK (2005) Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolaemia. Hum Mol Genet 14: 1161-1169.
192. Szumska D, Pieles G, Essalmani R, Bilski M, Mesnard D, Kaur K, Franklyn A, El Omari K, Jefferis J, Bentham J, et al. (2008) VACTERL/caudal regression/Currarino syndrome-like malformations in mice with mutation in the proprotein convertase Pcsk5. Genes Dev 22: 1465-1477.
193. Tagliabracci VS, Wiley SE, Guo X, Kinch LN, Durrant E, Wen J, Xiao J, Cui J, Nguyen KB, Engel JL, et al. (2015) A single kinase generates the majority of the secreted phosphoproteome. Cell 161: 1619-1632.
194. Talmud PJ, Shah S, Whittall R, Futema M, Howard P, Cooper JA, Harrison SC, Li K, Drenos F, Karpe F, et al. (2013) Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet 381: 1293-1301.
195. Tavori H, Christian D, Minnier J, Plubell D, Shapiro MD, Yeang C, Giunzioni I, Croyal M, Duell PB, Lambert G, et al. (2016) PCSK9 association with lipoprotein(a). Circ Res 119: 29-35.
196. Taylor NA, Van De Ven WJ, and Creemers JW (2003) Curbing activation: proprotein convertases in homeostasis and pathology. FASEB J 17: 1215-1227.
197. Thedrez A, Sjouke B, Passard M, Prampart-Fauvet S, Guédon A, Croyal M, Dallinga-Thie G, Peter J, Blom D, Ciccarese M, et al. (2016) Proprotein convertase subtilisin kexin type 9 inhibition for autosomal recessive hypercholesterolemia-brief report. Arterioscler Thromb Vasc Biol 36: 1647-1650.
198. Timms KM, Wagner S, Samuels ME, Forbey K, Goldfine H, Jammulapati S, Skolnick MH, Hopkins PN, Hunt SC, and Shattuck DM (2004) A mutation in PCSK9causing autosomal-dominant hypercholesterolemia in a Utah pedigree. Hum Genet 114: 349-353.
199. Topchiy E, Cirstea M, Kong HJ, Boyd JH, Wang Y, Russell JA, and Walley KR (2016) Lipopolysaccharide is cleared from the circulation by hepatocytes via the low density lipoprotein receptor. PLoS One 11: e0155030.
200. Turpeinen H, Ortutay Z, and Pesu M (2013) Genetics of the first seven proprotein convertase enzymes in health and disease. Curr Genomics 14: 453-467.
201. Uchida L, Urata S, Ulanday GE, Takamatsu Y, Yasuda J, Morita K, and Hayasaka D (2016) Suppressive effects of the site 1 protease (S1P) inhibitor, PF-429242, on dengue virus propagation. Viruses 8: E46.
202. Ueyama C, Horibe H, Yamase Y, Fujimaki T, Oguri M, Kato K, Arai M, Watanabe S, Murohara T, and Yamada Y (2015) Association of FURIN and ZPR1 polymorphisms with metabolic syndrome. Biomed Rep 3: 641-647.
203. Varret M, Rabès JP, Saint-Jore B, Cenarro A, Marinoni JC, Civeira F, Devillers M, Krempf M, Coulon M, Thiart R, et al. (1999) A third major locus for autosomal dominant hypercholesterolemia maps to 1p34.1-p32. Am J Hum Genet 64: 1378-1387.
204. Walley KR, Thain KR, Russell JA, Reilly MP, Meyer NJ, Ferguson JF, Christie JD, Nakada TA, Fjell CD, Thair SA, et al. (2014) PCSK9 is a critical regulator of the innate immune response and septic shock outcome. Sci Transl Med 6: 258ra143.
205. Weider E, Susan-Resiga D, Essalmani R, Hamelin J, Asselin MC, Nimesh D, Ashraf Y, Wycoff KL, Zhang J, Prat A, et al. (2016) Proprotein convertase subtilisin/kexin type 9 (PCSK9) single domain antibodies are potent inhibitors of low density lipoprotein receptor degradation. J Biol Chem 291: 16659-16671.
206. Wetsel WC, Rodriguiz RM, Guillemot J, Rousselet E, Essalmani R, Kim IH, Bryant JC, Marcinkiewicz J, Desjardins R, Day R, et al. (2013) Disruption of the expression of the proprotein convertase PC7 reduces BDNF production and affects learning and memory in mice. Proc Natl Acad Sci USA 110: 17362-17367.
207. Xiao HB, Sun ZL, Zhang HB, and Zhang DS (2012) Berberine inhibits dyslipidemia in C57BL/6 mice with lipopolysaccharide induced inflammation. Pharmacol Rep 64: 889-895.
208. Yamamoto T, Lu C, and Ryan RO (2011) A two-step binding model of PCSK9 interaction with the low density lipoprotein receptor. J Biol Chem 286: 5464-5470.
209. Yan W, Wu F, Morser J, and Wu Q (2000) Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme. Proc Natl Acad Sci USA 97: 8525-8529.
210. Yang J, Goldstein JL, Hammer RE, Moon YA, Brown MS, and Horton JD (2001) Decreased lipid synthesis in livers of mice with disrupted Site-1 protease gene. Proc Natl Acad Sci USA 98: 13607-13612.
211. Yao C, Chen BH, Joehanes R, Otlu B, Zhang X, Liu C, Huan T, Tastan O, Cupples LA, Meigs JB, et al. (2015) Integromic analysis of genetic variation and gene expression identifies networks for cardiovascular disease phenotypes. Circulation 131: 536-549.
212. Yue P, Averna M, Lin X, and Schonfeld G (2006) The c.43_44insCTG variation in PCSK9 is associated with low plasma LDL-cholesterol in a Caucasian population. Hum Mutat 27: 460-466.
213. Zaid A, Roubtsova A, Essalmani R, Marcinkiewicz J, Chamberland A, Hamelin J, Tremblay M, Jacques H, Jin W, Davignon J, et al. (2008) Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology 48: 646-654.
214. Zhang DW, Garuti R, Tang WJ, Cohen JC, and Hobbs HH (2008) Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor. Proc Natl Acad Sci USA 105: 13045-13050.
215. Zhang DW, Lagace TA, Garuti R, Zhao Z, McDonald M, Horton JD, Cohen JC, and Hobbs HH (2007) Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem 282: 18602-18612.
216. Zhao Z, Tuakli-Wosornu Y, Lagace TA, Kinch L, Grishin NV, Horton JD, Cohen JC, and Hobbs HH (2006) Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet 79: 514-523.